Group 1 - The Shanghai Composite Index fell by 0.46% to close at 3666.44 points, while the Hang Seng Index decreased by 0.37% to 25519.32 points [1] - Qingdao Port's AH premium reached 43.84%, ranking it 78th in terms of AH stock premium rates [1] - On the closing day, Qingdao Port's A-shares were priced at 8.77 yuan, down 0.79%, and H-shares were at 6.67 HKD, down 1.04% [1] Group 2 - Qingdao Port International Co., Ltd. was established on November 15, 2013, and was listed on the Hong Kong Stock Exchange on June 6, 2014, and on the Shanghai Stock Exchange on January 21, 2019 [1] - The company is a major operator of Qingdao Port, which has been operational since 1892, managing five key port areas: Qianwan, Huangdao Oil Port, Dongjiakou, Dagang, and Weihai [1] - Qingdao Port provides various services including loading and unloading of containers, metal ores, coal, crude oil, logistics, and port value-added services, benefiting from its strategic location as a key international trade hub in Northeast Asia and a significant point on the "Belt and Road" initiative [1]

Group 1 - The Shanghai Composite Index fell by 0.46% to close at 3666.44 points, while the Hang Seng Index decreased by 0.37% to 25519.32 points [1] - China Eastern Airlines' A/H premium reached 42.29%, ranking 82nd among A/H shares [1] - At market close, China Eastern Airlines' A-shares were priced at 3.85 yuan, down 0.52%, and H-shares were at 2.96 HKD, down 0.67% [1] Group 2 - China Eastern Airlines, headquartered in Shanghai, is one of China's three major state-owned airlines, with its origins tracing back to the establishment of the first flight squadron in January 1957 [1] - The airline operates a modern fleet of over 800 aircraft, making it one of the youngest fleets globally, and has the largest internet-enabled wide-body fleet in China [1] - China Eastern Airlines has pioneered the upgrade of in-flight Wi-Fi technology, allowing passengers to enjoy "full online" experiences without the previous 3000-meter altitude restriction [1] - As a global launch customer of the domestically produced C919 aircraft, China Eastern has successfully commenced commercial operations of this model [1] - The airline has established dual core hubs in Beijing and Shanghai, along with regional hubs in Xi'an and Kunming, covering all provincial capitals and airports with over 10 million passengers [1]

Group 1 - The Shanghai Composite Index rose by 0.5% to close at 3665.92 points, while the Hang Seng Index increased by 0.25% to 24969.68 points [1] - Zhongyuan Securities' AH premium reached 77.6%, ranking 41st among AH shares [1] - At the close, Zhongyuan Securities' A-shares were priced at 4.49 yuan, with a gain of 0.45%, and H-shares were priced at 2.76 HKD, up by 1.47% [1] Group 2 - Zhongyuan Securities Co., Ltd. was established on November 8, 2002, and is a key player in the capital market development in Henan [1] - It is one of the 140+ securities firms in China that are listed on both the Hong Kong and domestic main boards, having successfully listed in Hong Kong in June 2014 and on the Shanghai Stock Exchange in January 2017 [1] - Zhongyuan Securities has developed into a comprehensive brokerage firm with a focus on research, investment banking, investment business, wealth management, and asset management, ranking 9th in the industry for the number of companies sponsored for listing and approval rate by the end of 2021 [1]

Group 1 - The Shanghai Composite Index rose by 0.5% to close at 3665.92 points, while the Hang Seng Index increased by 0.25% to 24969.68 points [1] - CanSino Biologics has an AH premium of 91.3%, ranking 35th among AH shares. The A-shares closed at 82.5 yuan, down 3.06%, and the H-shares closed at 47.08 HKD, down 6.96% [1] - CanSino Biologics, founded in 2009 in China, focuses on providing innovative, high-quality, and accessible vaccines for the prevention and treatment of infectious diseases, positioning itself as a leading high-tech biopharmaceutical company [1] Group 2 - The company's mission is to provide innovative, high-quality, and accessible vaccines globally, aiming for the vision of "Innovation without end, a world without epidemics" [1] - CanSino Biologics is listed on both the Hong Kong Stock Exchange (H shares, stock code 6185.HK) and the Shanghai Stock Exchange's STAR Market (A shares, stock code 688185), being the first "A+H" vaccine stock since the launch of the STAR Market [1]

Core Points - The Shanghai Composite Index rose by 0.5% to close at 3665.92 points, while the Hang Seng Index increased by 0.25% to 24969.68 points [1] - Longyuan Power's A/H share premium reached 162.6%, ranking sixth among A/H shares [1] - Longyuan Power's A-shares closed at 16.91 yuan, with a gain of 0.24%, and H-shares closed at 7.03 HKD, up by 0.14% [1] Company Overview - Longyuan Power Group Co., Ltd. was established in 1993 and has undergone several ownership changes, currently under the State Energy Group [1] - The company successfully listed on the Hong Kong main board in 2009 and is recognized as "China's first new energy stock" [1] - In 2022, Longyuan Power became the first H-share new energy power generation central enterprise to return to A-shares, marking several firsts in the domestic capital market [1] - Longyuan Power is a pioneer in wind power development in China, leading in offshore, low wind speed, and high altitude wind power sectors [1] - Since 2015, Longyuan Power has maintained its position as the world's largest wind power operator [1]

Company Overview - China Oilfield Services Limited (COSL) is a major integrated oilfield service provider globally, offering services across all stages of offshore oil and gas exploration, development, and production [1] - COSL's business is divided into four main categories: geophysical exploration services, drilling services, oilfield technical services, and marine services [1] Stock Performance - On August 12, the Shanghai Composite Index rose by 0.5%, closing at 3665.92 points, while the Hang Seng Index increased by 0.25%, closing at 24969.68 points [1] - COSL's A-shares closed at 14.01 yuan, with an increase of 0.79%, while its H-shares closed at 7.2 Hong Kong dollars, up by 1.84% [1] A/H Share Premium - COSL's A/H share premium reached 112.43%, ranking it 22nd among A/H shares in terms of premium rate [1][2]

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **pharmaceutical and medical device industry** in China, particularly the performance and outlook of various companies within this sector [1][2][3]. Core Insights and Arguments - **Medical Device Sector Growth**: The medical device sector is expected to achieve positive growth in the second half of the year, following significant inventory reduction in the first half, leading to a low base effect. Companies like **Mindray Medical** and **United Imaging** are recommended for investment [1][2]. - **International Market Potential**: The domestic market shows steady growth, but overseas markets, particularly in Europe, Asia, Africa, and Latin America, present significant opportunities. Companies such as **Mindray**, **New Industry Bio**, **Nanwei Software**, and **Newmed** are highlighted for their overseas business expansion, expected to show results starting in 2026 [1][5]. - **Traditional Chinese Medicine (TCM)**: The TCM sector is anticipated to improve in Q3 due to low base effects, reduced inventory, and cost improvements, with companies like **Jichuan Pharmaceutical**, **Kweichow Moutai**, and **Shenwei Pharmaceutical** being of interest [1][6]. - **Biopharmaceuticals**: **Ganli Pharmaceutical** is noted for its strong performance in the insulin market, with high likelihood of completing stock incentives. The competitive landscape for insulin weekly formulations is favorable, and companies like **Anke Bio** and **Changchun High-tech** are also recommended [1][6]. - **Innovation in Drug Development**: There is a diversification in funding sources for innovative drug research and development, with a positive trend in both primary market financing and the establishment of industrial funds. The IPO wave for innovative drugs in Hong Kong is expected to surpass the previous cycle, aided by the loosening of listing regulations for unprofitable companies in A-shares [1][8][9]. Additional Important Insights - **Pricing Trends**: The medical device industry has seen a stabilization in pricing, with most products already undergoing centralized procurement. Future price declines are not expected, and the overall pricing environment is becoming more stable [3][4]. - **BD (Business Development) Trends**: The BD upfront payments have become a significant source of funding for R&D in innovative drugs, enhancing companies' willingness to invest in research. The trend indicates a gradual improvement in R&D investment in China [10]. - **Policy Impact**: Recent domestic policies have been favorable for the innovative drug sector, with expectations for more supportive measures to be introduced. The ongoing negotiations for medical insurance in the second half of the year may further reflect this support [12]. - **International Recognition**: Chinese companies are gaining international recognition for their R&D capabilities, leading to substantial BD transactions in areas like ADC and GLP-1 weight loss drugs, indicating a pivotal moment for Chinese innovation on the global stage [13]. - **Performance of Innovative Companies**: Companies like **BeiGene** and **Innovent Biologics** have shown positive earnings trends, with significant upcoming academic conferences expected to provide critical data supporting future BD transactions [14]. Valuation and Market Dynamics - **AH Premium Trends**: The premium for A-shares over H-shares has been narrowing, with leading companies like **Hengrui Medicine** and **WuXi AppTec** showing signs of premium recovery. As of August 1, 2025, Hengrui's AH premium was -10.37%, while WuXi's was 0.40% [15][17]. - **Future Valuation Predictions**: The Hong Kong pharmaceutical sector is still in a valuation recovery phase, with expectations for the AH premium to continue narrowing as Chinese innovative drug companies expand their international presence [19].

Group 1 - The Shanghai Composite Index rose by 0.96% to close at 3617.6 points, while the Hang Seng Index increased by 0.68% to 24902.53 points [1] - Hongye Futures has the highest A/H premium at 208.79%, with its A-shares closing at 12.3 yuan, up 1.74%, and H-shares at 4.35 HKD, up 3.33% [1] - Hongye Futures Co., Ltd. was established in 1995 and is a state-owned enterprise fully owned by Jiangsu Provincial State-owned Assets Supervision and Administration Commission [1] Group 2 - The company operates in various sectors including commodity futures brokerage, financial futures brokerage, futures investment consulting, asset management, and fund sales [1] - Hongye Futures has established 38 branches in major financial centers and key cities across China, ranking among the top in the country [1] - The company has received multiple honors, including "National Civilized Unit" and "China's Best Futures Company" [1]

Group 1 - The Shanghai Composite Index rose by 0.96% to close at 3617.6 points, while the Hang Seng Index increased by 0.68% to 24902.53 points [1] - China Oilfield Services Limited (COSL) has an AH premium of 117.32%, ranking 22nd among AH shares [1] - COSL's A-shares closed at 13.87 yuan with a gain of 0.22%, and H-shares closed at 6.97 HKD, up by 0.58% [1] Group 2 - COSL is a major integrated oilfield service provider globally, offering services across all stages of offshore oil and gas exploration, development, and production [1] - The company's services are categorized into four main types: geophysical exploration services, drilling services, oilfield technical services, and marine services [1] - COSL was publicly listed on the Hong Kong Stock Exchange on November 20, 2002, and has been trading in the U.S. OTC market since March 26, 2004, and on the Shanghai Stock Exchange since September 28, 2007 [1]

本文源自：金融界 作者：行情君 资料显示，上海复旦张江生物医药股份有限公司,一九九六年十一月创建于上海浦东张江高科技园区,由 知名企业如上海医药集团股份有限公司等作为公司股东。本着"我们多一分探索、人类多一分健康"的信 念,公司主要从事生物医药的创新研究、开发、生产和销售,力求成为一家以知识产权为核心源泉的生物 医药创新企业。经过多年的不懈努力,公司在基因技术药物、光动力技术药物、纳米技术药物及口服固 体制剂技术药物等领域不断推出新技术及产品,形成了明显的竞争优势,预计未来将陆续有新药投放市 场。凭籍在生物医药领域的实力,公司多次承担"国家重点科技项目(攻关)计划"、"国家高技术研究发展 计划(八六三计划)"、"'重大新药创制'科技重大专项"等。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 8月5日，上证指数涨0.96%，收报3617.6点，恒生指数涨0.68%，收报24902.53点。 复旦张江AH溢价达177.33%，位居AH股溢价率第四位。当日收盘，复旦张江A股报10.92元，跌幅 0.27%，H股报4.3港元，上涨1.65%。 ...